Integrity Alliance LLC. Invests $706,000 in Sanofi $SNY

Key Points

• Integrity Alliance LLC has invested approximately $706,000 in Sanofi, acquiring 12,733 shares in the company during the first quarter.
• Despite a recent earnings miss of $0.90 EPS against an estimate of $0.96, Sanofi reported robust revenue of $11.34 billion for the quarter.
• Wall Street analysts show optimism on Sanofi, with many adjusting their ratings to buy and an average target price of $62.67.

Integrity Alliance LLC. bought a new position in shares of Sanofi (NASDAQ:SNY - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 12,733 shares of the company's stock, valued at approximately $706,000.

Other large investors also recently modified their holdings of the company. Accent Capital Management LLC acquired a new position in shares of Sanofi during the first quarter worth approximately $29,000. Eastern Bank lifted its position in shares of Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after purchasing an additional 300 shares in the last quarter. Golden State Wealth Management LLC lifted its position in shares of Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares in the last quarter. Banque Transatlantique SA acquired a new position in shares of Sanofi during the first quarter worth approximately $33,000. Finally, Brentview Investment Management LLC acquired a new position in shares of Sanofi during the first quarter worth approximately $42,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 1.0%

Sanofi stock opened at $47.65 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The firm's fifty day moving average price is $48.68 and its two-hundred day moving average price is $51.21. Sanofi has a 1-year low of $44.73 and a 1-year high of $60.12. The firm has a market capitalization of $117.01 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same period in the prior year, the firm posted $1.73 EPS. The business's revenue was down 7.0% on a year-over-year basis. On average, equities research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Guggenheim restated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Finally, Barclays reissued an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.